Document Type
Article
Publication Date
7-31-2019
ISSN
2041-1723
Publisher
Springer Nature
Language
en-US
Abstract
In the face of rising rates of antibacterial resistance, many responses are being pursued in parallel, including ‘non-traditional’ antibacterial agents (agents that are not small-molecule drugs and/or do not act by directly targeting bacterial components necessary for bacterial growth). In this Perspective, we argue that the distinction between traditional and nontraditional agents has only limited relevance for regulatory purposes. Rather, most agents in both categories can and should be developed using standard measures of clinical efficacy demonstrated with non-inferiority or superiority trial designs according to existing regulatory frameworks. There may, however, be products with non-traditional goals focused on population-level benefits that would benefit from extension of current paradigms. Discussion of such potential paradigms should be undertaken by the development community.
Recommended Citation
Kevin Outterson, John Rex, Holly Fernandez Lynch, I. Glen Cohen & Jonathan Darrow,
Designing Development Programs for Non-Traditional Antibacterial Agents
,
in
10
Nature Communications
3416
(2019).
Available at:
https://scholarship.law.bu.edu/faculty_scholarship/654
